ZHANG Xiaoyun 1 , ZHU Xinrui 1 , PENG Wei 1 , LIU Chang 1 , LI Chuan 1 , LI Qiu 2 , CHEN Weixia 3 , LI Zhiping 4 , LU Qiang 5 , LU Wusheng 1 , YAN Lünan 1 , YANG Jiayin 1 , WEN Tianfu 1
  • 1. Department of Liver Surgery/Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 2. Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 3. Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 4. Department of Abdominal Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 5. Department of Ultrasound, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
WEN Tianfu, Email: wentianfu@scu.edu.cn
intermediate and advanced hepatocellular carcinoma; conversion resection; lenvatinib; transarterial chemoembolization; programmed cell death protein-1 antibody
10.7507/1007-9424.202111006
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To explore the safety and effectiveness of transarterial chemoembolization (TACE) combined with lenvatinib and programmed cell death protein-1 (PD-1) antibody in the conversion resection for intermediate and advanced unresectable hepatocellular carcinoma (HCC), and to provide new treatment strategies for the treatment of intermediate and advanced unresectable HCC. Method Thirty-eight intermediate and advanced unresectable HCC patients treated at West China Hospital of Sichuan University from October 2020 to June 2021 were prospectively included in our study, all patients treated with TACE + lenvatinib + PD-1 antibody, and the clinical data of these 38 patients were summarized. Results The last evaluation time for the 38 patients was October 20, 2021. According to the mRECIST standard for tumor efficacy evaluation, the objective response rate was 84.2% (32/38), the disease control rate was 94.7% (36/38); the conversion success rate based on imaging was 55.3% (21/38), the actual conversion resection rate was 52.6% (20/38). The incidence of adverse events was 100%, of which 22 patients had grade 3 adverse events, and there was no ≥ grade 4 adverse events. All patients were followed up, the follow-up time was 16–52 weeks, and the median follow-up time was 33.5 weeks. During the follow-up period, only two patients had tumor progression, of which one patient died due to disease progression, and there was no postoperative recurrence. Conclusions Lenvatinib combined with TACE and PD-1 antibody is safe for the treatment of intermediate and advanced unresectable HCC. Triple therapy can achieve satisfactory conversion resection rate of intermediate and advanced unresectable HCC, which will provide a new treatment strategy for it.

Citation： ZHANG Xiaoyun, ZHU Xinrui, PENG Wei, LIU Chang, LI Chuan, LI Qiu, CHEN Weixia, LI Zhiping, LU Qiang, LU Wusheng, YAN Lünan, YANG Jiayin, WEN Tianfu. The safety and efficacy of transarterial chemoembolization + lenvatinib + PD-1 antibody in the conversion resection for intermediate and advanced unresectable hepatocellular carcinoma: a prospective cohort study and preliminary report. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(1): 39-45. doi: 10.7507/1007-9424.202111006 Copy

  • Previous Article

    A single-center retrospective analysis of surgical strategy and clinical outcome of pulmonary nodules using pulmonary subsegments as anatomical unit

  • Next Article

    Diagnostic utility of electromagnetic navigation bronchoscopy combined with radial endobronchial ultrasound in peripheral pulmonary lesions